Genomma Lab Internacional (GNMLF) Stock Price, News & Analysis

Company Overview

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.

Key Stats

• Today's Range: $1.12 to $1.12
• 50-Day Range: $1.09 to $1.24
• 52-Week Range: $0.97 to $1.43
• Volume: N/A
• Average Volume: 1,600 shs
• Market Capitalization: N/A
• P/E Ratio: 0.66
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNMLF Stock Analysis - Frequently Asked Questions

How have GNMLF shares performed this year?

Genomma Lab Internacional's stock was trading at $1.27 at the beginning of 2025. Since then, GNMLF stock has decreased by 11.8% and is now trading at $1.12.

How do I buy shares of Genomma Lab Internacional?

Shares of GNMLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/09/2025
• Next Earnings (Estimated): 7/23/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNMLF
• CIK: N/A
• Web: www.genommalab.com
• Phone: 525550810000
• Fax: N/A
• Employees: 1,614
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.66
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A